BioXcel Therapeutics, Inc. (BTAI)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, BioXcel Therapeutics, Inc. reported revenue of $642.0K, down 71.7% from the prior year. The company ran a net loss, with a net margin of -10887.4%. It held $44.92M in total assets against $140.38M in total liabilities.
Key ratios (FY2025)
-7860.0%
Operating margin
-10887.4%
Net margin
-71.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $642.0K | $2.27M | $1.38M | $375.0K | — | — | — | — | — |
| Cost of Revenue | $164.0K | $2.14M | $1.26M | $20.0K | — | — | — | — | — |
| Operating Income | -$50.46M | -$67.25M | -$171.78M | -$159.65M | -$106.94M | -$82.30M | -$33.60M | -$19.96M | -$4.54M |
| Net Income | -$69.90M | -$59.60M | -$179.05M | -$165.76M | -$106.93M | -$82.17M | -$32.97M | -$19.27M | -$4.54M |
| EPS (Diluted) | $-5.73 | $-23.51 | $-98.33 | $-5.92 | $-4.05 | $-3.79 | — | — | — |
| Total Assets | $44.92M | $38.34M | $73.70M | $205.85M | $239.44M | $219.94M | $36.39M | $43.55M | $1.35M |
| Total Liabilities | $140.38M | $131.44M | $130.21M | $129.08M | $17.77M | $13.24M | $9.50M | $4.66M | $2.34M |
| Shareholders' Equity | -$95.46M | -$93.10M | -$56.51M | $76.78M | $221.67M | $206.70M | $26.89M | $38.89M | -$982.0K |
| Cash & Equivalents | $28.41M | $29.85M | $65.22M | $193.72M | $232.97M | $213.12M | $32.43M | $42.56M | $887.0K |
| Operating Cash Flow | -$57.62M | -$72.03M | -$155.01M | -$135.34M | -$82.15M | -$66.35M | -$27.10M | -$13.51M | -$2.20M |
| Capital Expenditures | $0 | $0 | $20.0K | $139.0K | $445.0K | $316.0K | $870.0K | $340.0K | — |
| Shares Outstanding | 22.33M | 3.10M | 1.87M | 28.15M | 27.98M | 24.42M | 18.09M | 15.66M | 9.91M |